AMG 162是以静脉注射给药，它的起效机理在于抑制骨母细胞的活性，骨母细胞主要吸收和消除陈骨并给新骨组织腾出空间。
The injectable treatment, called AMG 162, works by suppressing the activity of osteoclasts, the cells involved in absorbing and removing old bone so that new bone tissue can take its place.
目的：探讨颌骨骨母细胞瘤的临床和病理特点。
PURPOSE: to explore the clinicopathologic characteristics of osteoblastoma in the jaws.
结论：全面了解颌骨骨母细胞瘤的发病情况及病理特点，对其诊疗具有一定的临床价值。
CONCLUSION: It is valuable to study the clinicopathologic characteristics of osteoblastoma in the jaws for better diagnosis and treatment.
距骨软骨母细胞瘤病人发病年龄较大，病灶刮除植骨术是其治疗方法，；
Curettage and bone grafting is satisfactory therapy for chondroblastoma in talus. All patients do not relapse.
结果：颌骨骨母细胞瘤以10 ~30岁发病最多，部位以磨牙区最多，局部膨隆与钝性疼痛为主要临床症状。
RESULTS: the highest incidence age ranged from 10 to 30 years. The lesion seemed to occur most frequently in the molar region. Localized swelling and dull pain were the main symptoms.
结果：颌骨骨母细胞瘤以10 ~30岁发病最多，部位以磨牙区最多，局部膨隆与钝性疼痛为主要临床症状。
RESULTS: the highest incidence age ranged from 10 to 30 years. The lesion seemed to occur most frequently in the molar region. Localized swelling and dull pain were the main symptoms.
应用推荐